A Phase 3 interventional study of Empagliflozin and Placebo in Heart Failure, sponsored by Boehringer Ingelheim. Completed at 619 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-06.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing empagliflozin in Heart Failure — 16 open to participants now, 22 under way, 7 of them phase 3. empagliflozin · Heart Failure.
Among the 51 studies testing empagliflozin in Heart Failure, this one is the 2nd largest by enrollment, is one of 9 that started in 2017, is one of 14 in phase 3, and was the 3rd registered.
6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →16 of the 51 studies testing empagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
Christian Schulze · Sites in Germany
Ages 18+
Ain Shams University · Sites in Egypt
Ages 1 mo–18 yrs
University of Alberta · Sites in Canada
Ages 18+
Fazaia Ruth Pfau Medical College · Sites in Pakistan
Ages 40–70
By country, each count listing its studies:
empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 15 · Phase 4 16
First in 2017; this study’s year is marked. 9 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5,988 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 90 across the 51 interventional studies. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 51 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
14 studies in Heart Failure by Boehringer Ingelheim: 4 open now, 4 under way, 2 of them phase 3. Of 10 finished, 9 (90%) have results posted.
Among the 14 studies in Heart Failure by Boehringer Ingelheim, this one is one of 2 that started in 2017, is one of 8 in phase 3, and was the 2nd registered.
Boehringer Ingelheim’s Heart Failure studies by the year they started, since 2009.
8 of the studies testing empagliflozin in Heart Failure that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05392764Phase 3Juntendo UniversityEarly Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure | 2026-12-31 |
| NCT05879276Phase 3Central Hospital, Nancy, FranceEffect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. | 2027-03-16 |
| NCT07038356Phase 3Christian SchulzeEffects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure | 2027-04-30 |
| NCT07692256Ain Shams Universitythe Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients | 2026-12-01 |
| NCT06260059Anita SarafEfficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease | 2026-12-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 51 studies testing empagliflozin in Heart Failure, from their registry updates:
Among Boehringer Ingelheim’s 14 in Heart Failure:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study in adults with chronic heart failure. People with chronic heart failure may need to be hospitalised for their condition. Some people with chronic heart failure may eventually die from their condition. The purpose of the study is to find out whether a medicine called empagliflozin lowers the chances of patients having to go to hospital for heart failure and whether it improves their survival. The study is open to patients with a type of chronic heart failure called chronic heart failure with preserved ejection fraction.
Participants stay in the study until researchers have enough information about how effective empagliflozin is. It is expected that participants who enter at the very beginning of the enrolment period may be in the study for over 3 years, while participants who enter near the end of the enrolment period may be in the study for less than 2 years. The participants are put into 2 groups. It is decided by chance who gets into which group. One group gets empagliflozin tablets every day and the other group gets placebo tablets every day. Placebo tablets look like empagliflozin tablets but contain no medicine.
Participants visit the doctors regularly. During these visits, the doctors collect information about the participant's health. The doctors want to know how many patients had to go to hospital because of heart failure or who died from cardiovascular disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Empagliflozin
Drug: Placebo
once daily
Also known as: JARDIANCE, JARDIANZ, GIBTULIO
once daily
Time to First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF)
Failure with preserved Ejection Fraction (HFpEF). The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed: Incidence rate per 100 pt-yrs = 100 \* number of patients with event / time at risk \[years\]. Time at risk \[years\] = Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier.
Time frame: From randomization until completion of the planned treatment phase, up to 1403 days.
Occurrence of Adjudicated Hospitalisation for Heart Failure (HHF) (First and Recurrent)
Reported is the total number of adjudicated HHF events (first and recurrent) which occurred.
Time frame: From randomization until completion of the planned treatment phase, up to 1403 days.
eGFR (CKD-EPI) cr Slope of Change From Baseline
Glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR(CKD-EPI)cr) slope of change from baseline. Available on-treatment change-from-baseline data were used. The slope represents the long term effect of eGFR change from baseline and provides the yearly rate of decline. Timepoints after baseline were included in calculation of slope of change from baseline. The slope per patient was calculated using a random coefficient model with terms for treatment, region, baseline status of diabetes, age, sex, left ventricular ejection fraction (LVEF) and glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula (eGFR (CKD-EPI)cr) at baseline and in addition the factors "time", "treatment-by-time interaction", and "baseline eGFR (CKD-EPI)cr-by-time interaction".
Time frame: At baseline, week 4, 12, 32, 52, 76, 100, 124, 148, 172 and week 196, up to 1043 days.
Time to the First Event in the Composite Renal Endpoint: Chronic Dialysis, Renal Transplant, or Sustained Reduction in eGFR (CKD-EPI)cr
Chronic dialysis was defined as dialysis with a frequency of twice per week or more for at least 90 days. Sustained was determined by two or more consecutive post-baseline central laboratory measurement separated by at least 30 days. Reduction in glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr) was defined as reduction in eGFR from baseline ≥40%, eGFR \<15 mL/min/1.73 m\^2 for patients with baseline eGFR ≥30 mL/min/1.73 m\^2, or eGFR \<10 mL/min/1.73 m\^2 for patients with baseline eGFR \<30 mL/min/1.73 m\^2. The incidence rate per 100 patient years (100 \* number of patients with event / time at risk \[years\]) is reported. Time at risk \[year\] is calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Abbreviation: Patient-years (pt-yrs).
Time frame: From randomization until completion of the planned treatment phase, up to 1403 days.
Time to First Adjudicated Hospitalisation for Heart Failure (HHF)
Time to first adjudicated HHF. The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed: Incidence rate per 100 pt-yrs = 100 \* number of patients with event / time at risk \[years\]. Time at risk \[years\] = Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier.
Time frame: From randomization until completion of the planned treatment phase, up to 1403 days.
Time to Adjudicated Cardiovascular (CV) Death
Time to adjudicated CV death. The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed: Incidence rate per 100 pt-yrs = 100 \* number of patients with event / time at risk \[years\]. Time at risk \[years\] = Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier.
Time frame: From randomization until completion of the planned treatment phase, up to 1403 days.
Time to All-cause Mortality
Time to all-cause mortality. The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed: Incidence rate per 100 pt-yrs = 100 \* number of patients with event / time at risk \[years\]. Time at risk \[years\] = Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier.
Time frame: From randomization until completion of the planned treatment phase, up to 1403 days.
Time to Onset of Diabetes Mellitus (DM) in Patients With Pre-DM
Time to onset of DM (defined as HbA1c ≥6.5% or as diagnosed by the investigator) in patients with pre-DM. Pre-DM was defined as no history of DM and no HbA1c ≥6.5% before treatment, and a pre-treatment HbA1c value of ≥5.7% and \<6.5%. The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed: Incidence rate per 100 pt-yrs = 100 \* number of patients with event / time at risk \[years\]. Time at risk \[years\] = Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier.
Time frame: From randomization until completion of the planned treatment phase, to 1403 days.
Change From Baseline in Kansas City Cardiomyopathy Questionaire (KCCQ) Clinical Summary Score at Week 52
The KCCQ is a 23-item self-administered questionnaire designed to evaluate physical limitations, symptoms (frequency, severity, and changes over time), social limitations, self-efficacy, and quality of life in patients with Heart Failure. The KCCQ-clinical summary score comprises the following domains: Symptom frequency, symptom burden and physical limitation. The score is calculated by summing domain responses and then transforming scores to a 0-100 unit scale with higher scores indicating better health status. For patients who died, a worst score (score of 0) was imputed for the score at all subsequent scheduled visits after the date of death where the score would have been assessed. Change from baseline in KCCQ-score at week 52 was modeled using a MMRM with visit (week 12, 32 and 52) as repeated measures, adjusted mean (standard error) at week 52 is reported.
Time frame: At baseline and at week 12, week 32 and week 52.
Occurrence of All-cause Hospitalisation (First and Recurrent)
Occurrence of all-cause hospitalisation (first and recurrent). Total number of all cause hospitalisations is reported.
Time frame: From randomization until completion of the planned treatment phase, up to 1403 days.
A randomised, double-blind trial to demonstrate superiority of empagliflozin versus placebo in patients with symptomatic, chronic heart failure and preserved left ventricular ejection fraction (LVEF\>40%) under stable treatment of heart failure symptoms.
| Milestone | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Started | 2991 | 2997 |
| Treated | 2989 | 2996 |
| Completed | 2046 | 2051 |
| Not completed | 945 | 946 |
| Withdrew: Adverse event | 553 | 575 |
| Withdrew: Protocol violation | 30 | 24 |
| Withdrew: Lost to follow-up | 6 | 16 |
| Withdrew: Patient refusal to continue, not due to ae | 304 | 284 |
| Withdrew: Study drug stopped, reason missing | 6 | 1 |
| Withdrew: Medical advice | 6 | 2 |
| Withdrew: Due to covid-19 pandemic | 2 | 8 |
| Withdrew: Investigator decision | 2 | 0 |
| Withdrew: Patient decision | 5 | 2 |
| Withdrew: Not attending study visits | 3 | 0 |
| Withdrew: Patient moved away | 3 | 4 |
| Withdrew: Other reason than stated above | 23 | 29 |
| Withdrew: Not treated | 2 | 1 |
Failure with preserved Ejection Fraction (HFpEF). The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed: Incidence rate per 100 pt-yrs = 100 \* number of patients with event / time at risk \[years\]. Time at risk \[years\] = Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier.
| Patients with event/100 pt-yrs at risk | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Time to First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF) | 8.67 (7.94 to 9.44) | 6.86 (6.22 to 7.54) |
Reported is the total number of adjudicated HHF events (first and recurrent) which occurred.
| HHF events | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Occurrence of Adjudicated Hospitalisation for Heart Failure (HHF) (First and Recurrent) | 541 | 407 |
Glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR(CKD-EPI)cr) slope of change from baseline. Available on-treatment change-from-baseline data were used. The slope represents the long term effect of eGFR change from baseline and provides the yearly rate of decline. Timepoints after baseline were included in calculation of slope of change from baseline. The slope per patient was calculated using a random coefficient model with terms for treatment, region, baseline status of diabetes, age, sex, left ventricular ejection fraction (LVEF) and glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula (eGFR (CKD-EPI)cr) at baseline and in addition the factors "time", "treatment-by-time interaction", and "baseline eGFR (CKD-EPI)cr-by-time interaction".
| mL/min/ 1.73 meters squared/year | Placebo | 10 mg Empagliflozin |
|---|---|---|
| eGFR (CKD-EPI) cr Slope of Change From Baseline | -2.616 ± 0.108 | -1.253 ± 0.108 |
Chronic dialysis was defined as dialysis with a frequency of twice per week or more for at least 90 days. Sustained was determined by two or more consecutive post-baseline central laboratory measurement separated by at least 30 days. Reduction in glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr) was defined as reduction in eGFR from baseline ≥40%, eGFR \<15 mL/min/1.73 m\^2 for patients with baseline eGFR ≥30 mL/min/1.73 m\^2, or eGFR \<10 mL/min/1.73 m\^2 for patients with baseline eGFR \<30 mL/min/1.73 m\^2. The incidence rate per 100 patient years (100 \* number of patients with event / time at risk \[years\]) is reported. Time at risk \[year\] is calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Abbreviation: Patient-years (pt-yrs).
| Patients with event /100 pt-yrs at risk | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Time to the First Event in the Composite Renal Endpoint: Chronic Dialysis, Renal Transplant, or Sustained Reduction in eGFR (CKD-EPI)cr | 2.23 (1.84 to 2.66) | 2.13 (1.74 to 2.54) |
Time to first adjudicated HHF. The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed: Incidence rate per 100 pt-yrs = 100 \* number of patients with event / time at risk \[years\]. Time at risk \[years\] = Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier.
| Patients with event /100 pt-yrs at risk | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Time to First Adjudicated Hospitalisation for Heart Failure (HHF) | 5.97 (5.37 to 6.62) | 4.28 (3.78 to 4.82) |
Time to adjudicated CV death. The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed: Incidence rate per 100 pt-yrs = 100 \* number of patients with event / time at risk \[years\]. Time at risk \[years\] = Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier.
| Patients with event /100 pt-yrs at risk | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Time to Adjudicated Cardiovascular (CV) Death | 3.81 (3.35 to 4.31) | 3.42 (2.98 to 3.89) |
Time to all-cause mortality. The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed: Incidence rate per 100 pt-yrs = 100 \* number of patients with event / time at risk \[years\]. Time at risk \[years\] = Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier.
| Patients with event /100 pt-yrs at risk | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Time to All-cause Mortality | 6.67 (6.05 to 7.32) | 6.60 (5.98 to 7.24) |
Time to onset of DM (defined as HbA1c ≥6.5% or as diagnosed by the investigator) in patients with pre-DM. Pre-DM was defined as no history of DM and no HbA1c ≥6.5% before treatment, and a pre-treatment HbA1c value of ≥5.7% and \<6.5%. The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed: Incidence rate per 100 pt-yrs = 100 \* number of patients with event / time at risk \[years\]. Time at risk \[years\] = Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier.
| Patients with event /100 pt-yrs at risk | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Time to Onset of Diabetes Mellitus (DM) in Patients With Pre-DM | 7.39 (6.21 to 8.68) | 6.12 (5.07 to 7.26) |
The KCCQ is a 23-item self-administered questionnaire designed to evaluate physical limitations, symptoms (frequency, severity, and changes over time), social limitations, self-efficacy, and quality of life in patients with Heart Failure. The KCCQ-clinical summary score comprises the following domains: Symptom frequency, symptom burden and physical limitation. The score is calculated by summing domain responses and then transforming scores to a 0-100 unit scale with higher scores indicating better health status. For patients who died, a worst score (score of 0) was imputed for the score at all subsequent scheduled visits after the date of death where the score would have been assessed. Change from baseline in KCCQ-score at week 52 was modeled using a MMRM with visit (week 12, 32 and 52) as repeated measures, adjusted mean (standard error) at week 52 is reported.
| Score on a scale | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Change From Baseline in Kansas City Cardiomyopathy Questionaire (KCCQ) Clinical Summary Score at Week 52 | 3.18 ± 0.31 | 4.51 ± 0.31 |
Occurrence of all-cause hospitalisation (first and recurrent). Total number of all cause hospitalisations is reported.
| Events of all-cause hospitialisations | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Occurrence of All-cause Hospitalisation (First and Recurrent) | 2769 | 2566 |
Collected over [All-cause Mortality]: From study start until end of study, up to 1438 days. [Serious adverse events (AE) and other AE]:From time of the first drug intake until 7 days (Residual Effect Period) after the last drug intake, up to 1410 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 427/2,991 (14.3%) | 1,543/2,989 (51.6%) | 1,274/2,989 (42.6%) |
| 10 mg Empagliflozin | 422/2,997 (14.1%) | 1,436/2,996 (47.9%) | 1,191/2,996 (39.8%) |
| Event | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Cardiac failureCardiac disorders | 594/2989 | 448/2996 |
| PneumoniaInfections and infestations | 119/2989 | 100/2996 |
| Acute kidney injuryRenal and urinary disorders | 107/2989 | 81/2996 |
| Atrial fibrillationCardiac disorders | 80/2989 | 92/2996 |
| Cardiac failure congestiveCardiac disorders | 66/2989 | 57/2996 |
| DeathGeneral disorders | 38/2989 | 56/2996 |
| Acute myocardial infarctionCardiac disorders | 48/2989 | 50/2996 |
| COVID-19Infections and infestations | 47/2989 | 49/2996 |
| Renal impairmentRenal and urinary disorders | 42/2989 | 38/2996 |
| Ischaemic strokeNervous system disorders | 35/2989 | 42/2996 |
| Event | Placebo | 10 mg Empagliflozin |
|---|---|---|
| HypertensionVascular disorders | 248/2989 | 212/2996 |
| HypotensionVascular disorders | 176/2989 | 212/2996 |
| HyperuricaemiaMetabolism and nutrition disorders | 208/2989 | 131/2996 |
| Urinary tract infectionInfections and infestations | 160/2989 | 207/2996 |
| Diabetes mellitusMetabolism and nutrition disorders | 200/2989 | 139/2996 |
| HyperkalaemiaMetabolism and nutrition disorders | 194/2989 | 170/2996 |
| FallInjury, poisoning and procedural complications | 193/2989 | 189/2996 |
| Renal impairmentRenal and urinary disorders | 181/2989 | 177/2996 |
| AnaemiaBlood and lymphatic system disorders | 164/2989 | 119/2996 |
| Atrial fibrillationCardiac disorders | 156/2989 | 137/2996 |
Randomised Set (RS), including all randomised patients.
| Age, Continuous(Years) | Placebo | 10 mg Empagliflozin | Total |
|---|---|---|---|
| Mean | 71.9 ± 9.6 | 71.8 ± 9.3 | 71.9 ± 9.4 |
| Sex: Female, Male(Participants) | Placebo | 10 mg Empagliflozin | Total |
|---|---|---|---|
| Female | 1338 | 1338 | 2676 |
| Male | 1653 | 1659 | 3312 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 10 mg Empagliflozin | Total |
|---|---|---|---|
| Hispanic or Latino | 754 | 770 | 1524 |
| Not Hispanic or Latino | 2236 | 2227 | 4463 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Placebo | 10 mg Empagliflozin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 104 | 90 | 194 |
| Asian | 411 | 413 | 824 |
| Native Hawaiian or Other Pacific Islander | 19 | 14 | 33 |
| Black or African American | 125 | 133 | 258 |
| White | 2256 | 2286 | 4542 |
| More than one race | 75 | 60 | 135 |
| Unknown or Not Reported | 1 | 1 | 2 |
Showing the first 100 of 619 sites across 23 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2017 to primary completion in Apr 2021, 49 months.
Results were first posted in Jun 2022, 1 year 1 month after primary completion.
Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 49 months is above that.
Counting every sponsor, half of 151 studies reached it within 39 months; a quarter within 25 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empagliflozin